April 18, 2026-
Researchers at the University of Cambridge have developed a novel adeno-associated virus (AAV)-based gene delivery platform capable of inducing localized anti-inflammatory cytokine expression in the lungs, offering a potential new strategy to control respiratory inflammation without systemic side effects. The findings, published in Science Immunology, demonstrate how targeted gene delivery can reestablish immune balance in the lung microenvironment while preserving overall immune function.
The team engineered an AAV6.2-CC10 vector system to drive in situ expression of key immunomodulatory cytokines, including interleukin-2 (IL-2), interleukin-1 receptor antagonist (IL-1RA), and interleukin-10 (IL-10). Importantly, this approach enabled sustained cytokine production localized specifically to lung epithelial cells, with no detectable expression in peripheral tissues or disruption to systemic immune responses. The results highlight the precision of AAV-mediated delivery in achieving tissue-specific therapeutic effects.
In preclinical mouse models of respiratory infection, the platform demonstrated the ability to modulate disease severity. While IL-2 expression showed limited benefit—likely due to simultaneous activation of both regulatory and pro-inflammatory immune pathways—delivery of IL-1RA and IL-10 significantly reduced tissue damage and improved recovery outcomes. These cytokines also helped mitigate complications such as influenza-associated aspergillosis, with treated animals showing reduced neutrophil infiltration, less weight loss, and overall improved health.
The study underscores the broader therapeutic potential of localized cytokine delivery, particularly in the context of viral infections such as influenza and SARS-CoV-2, where excessive inflammation contributes to disease severity and increased mortality risk. By enabling sustained, localized cytokine expression over several weeks, the AAV platform may overcome longstanding limitations of cytokine-based biologics, including short half-life and systemic toxicity.
Despite these promising findings, the researchers note several challenges that remain before clinical translation. These include the need to evaluate repeat dosing, as AAV-based therapies can induce neutralizing antibodies that limit re-administration, and to validate the platform in human systems. Further studies using human cell models are expected to inform future preclinical development and potential therapeutic applications.
